The word does not name a treatment
Think of protein’s building blocks linked in a short chain: that is a peptide. The word names that structure; it gives no assurance of safety or lawful access.
Begin with the full medicine name. If the proposal is a blend, ask for each ingredient. Then ask what health problem the prescriber is trying to address. “Wellness” leaves a lot unsaid. A condition, a product and a reason for choosing it make a clearer starting point.
Approved products
The November 3, 2026 product check found FDA approvals for medicines containing tirzepatide (Mounjaro, Zepbound). Another example is semaglutide (Ozempic, Wegovy).
The federal drug agency whose name is shortened to FDA is the Food and Drug Administration. Keep the brand, form (such as a shot, pill or cream) and proposed use together when reading a product record. A name shared across an advertisement and a government page is a starting point for checking, rather than the end of the check.
A compounded product is a different kind of proposal
The person making the drug may be a licensed pharmacist or doctor; a registered facility (a drugmaking business registered with FDA) can make it as well. This process of preparing medicine for a particular need is called compounding.
That larger business is called a 503B outsourcing facility, after its section of federal law; it makes batches of sterile medicine, kept free of germs, often for clinics and hospitals. It need not be a licensed pharmacy.
The federal record as of November 3, 2026 is clear: FDA has not approved compounded drugs. Before these drugs reach the market, their benefit and safety have not been reviewed by FDA, nor has their quality.
If compounding comes up, ask which part of the person’s medical need an approved drug would leave unmet. Have the answer put in plain words. Ask for the pharmacy’s name as well, so the product discussion and the pharmacy check stay connected.
Copies and added vitamins
Under rules checked November 3, 2026, pharmacists and doctors cannot routinely compound close copies of medicines already sold ready-made. The restriction concerns copying the medicine itself, not just using its brand name. For an exception, the prescriber must decide the change produces a significant difference for the person named on that prescription.
A change might leave out a dye because of that person’s allergy. The prescriber has to decide whether the change makes that significant difference for that particular patient.
On that same review date, adding vitamin B12 to semaglutide did not by itself remove the restrictions on essentially copied products.
The rule calls such a product “essentially a copy.” That means the preparation resembles the available medicine closely enough to come under the restriction.
Ask how the proposed product fits the rule, rather than treating an added ingredient as the whole answer.
Read the October draft carefully
A draft policy dated October 30, 2026 was published by HHS, the Department of Health and Human Services. This proposed approach has no binding force. HHS proposes to hold off on legal action over some compounding when all the draft’s conditions are met. For a person offered one of these medicines, the proposal creates no right to have it compounded and gives it no FDA approval.
The draft includes the peptide ingredients KPV, epitalon and semax; none is part of an FDA-approved medicine in the November 3, 2026 review. The other named peptides, BPC-157, MOTS-c and TB-500, also have no FDA-approved medicine and are all subject to the draft’s conditions. For compounding by physicians or pharmacies licensed by a state, the draft concerns a single ingredient prescribed for a named person.
The exact ingredient and the way it is given must match Appendix B of the draft; this does not cover every shot, pill or other form. Blends, which combine ingredients, are excluded, as are the 503B outsourcing facilities that make drug batches.
Ask the prescriber to show where the proposed ingredient and way of taking it appear in that appendix.
To check whether the business is a 503B outsourcing facility, compare its name with FDA’s registered-facility list.
The term 503A refers to the part of federal law for making a medicine for a person named on a prescription. FDA’s formal 503A list of extra raw ingredients contained none of those six when checked on November 3, 2026. The proposed pause in legal action leaves that ingredient list unchanged. This HHS draft does not grant approval to a drug.
What the committee vote means
The HHS appendix describes a favorable July 2026 committee vote for six peptides out of seven. Such votes advise FDA. To change its formal ingredient list, the agency has to propose a rule and consider public comments.
The draft’s approach is called enforcement discretion. This means holding off on legal action under set conditions, without changing what the law allows.
Ask the prescriber which conditions apply to the proposed drug and what is still unclear.
Follow the claim to its source
What a drug directory entry proves
As checked November 3, 2026, a National Drug Code listing is not proof of FDA approval. It is an entry in a drug directory.
In guidance checked November 3, 2026, FDA rejects ads that equate a compounded drug with an approved medicine. It also rejects claims that it has been proved to give the same results as an approved drug.
When someone says “clinically proven,” ask proven for which product, which use and which outcome. Request the original record rather than a screenshot of a headline. If the answer concerns a different product, return to the proposal in front of you. A source is useful when it answers that proposal’s question.
Take the product name and your questions to the person assessing your health. Ask how the record fits the proposed use. Keep any gaps in that record on the list of things to discuss.